芪胶升白胶囊对非霍奇金淋巴瘤患者化疗后骨髓抑制的治疗作用观察

Effect of Qijiao Shengbai Capsuleon Bone Marrow Suppression of Patients with NHL

目的:观察芪胶升白胶囊对非霍奇金淋巴瘤患者化疗后骨髓抑制的治疗作用。方法:选取医院肿瘤科2012年1月—2016年1月收治的非霍奇金淋巴瘤患者324例,随机分为观察组(CHOP化疗方案+芪胶升白胶囊)与对照组(CHOP化疗方案),治疗4个周期后,观察两组患者的临床疗效、骨髓抑制及不良反应发生情况。结果:观察组患者总缓解率为58.60%,高于对照组的57.14%,两组患者见的总缓解率比较不具有统计学差异(P<0.05)。治疗结束后,观察组中重度骨髓抑制发生率为2.55%(4/157),显著低于对照组的15%(21/140);治疗结束1周后,观察组中重度骨髓抑制发生率为3.18%(5/157),显著低于对照组的17.14%(24/140),差异具有统计学意义(P<0.05)。观察组患者白细胞计数最低值为(2.61±0.57)×10~9/L,高于对照组的(1.21±0.31)×10~9/L,差异具有统计学意义(P<0.05);两组患者血红蛋白计数、血小板计数最低值比较无统计学差异(P<0.05)。治疗中,观察组患者有3(1.91%)例由于不良反应严重退出试验,对照组患者18(12.86%)例不良反应严重退出试验,观察组由于不良反应退出试验患者显著低于对照组(P<0.05)。治疗后,观察组患者贫血、感染及恶心呕吐的发生情况均显著低于对照组,差异具有统计学意义(P<0.05)。结论:芪胶升白胶囊能够改善恶性淋巴瘤患者骨髓抑制情况,降低不良反应发生率,保证化疗顺利进行,值得临床推广使用。

Objective： To observe the effect of Qijiao Shengbai Capsule in patients with NHL on bone marrow suppression after chemotherapy treatment. Methods： A total of 324 patients with NHL were randomly divided into observation group（ CHOP chemotherapy ＋ Qijiao Shengbai Capsule） and control group（ CHOP chemotherapy）. After four cycles of treatment,the clinical efficacy,adverse events and bone marrow suppression were observed. Results： The overall response rate in observation group was 58. 60% and the control group＇s was 57. 14%. There was no significant difference between two groups（ P〈0. 05）. After treatment,the observation group＇s severe marrow suppression was 2. 55%（ 4/157）,significantly lower than the control group＇s 15%（ 21/140）. 1 week after treatment,the observation group＇s incidence of severe marrow suppression was 3. 18%（ 5/157）,significantly lower than 17. 14%（ 24/140） in the control group. The difference was statistically significant（ P〈0. 05）. The lowest value of white blood cell count in the observation group was（ 2. 61 ± 0. 57） × 10~9/L,which was higher than the control group＇s（ 1. 21 ± 0. 31） × 10^9/L. The difference was statistically significant（ P〈0. 05）. The lowest value of the hemoglobin count and platelet count was not statistically significant（ P〈0. 05）. The observation group＇s patients had 3（ 1. 91%） cases due to the serious adverse reactions withdrawn from this study. The control group had 18（ 12. 86%）. After treatment,the incidence of anemia,infection,nausea and vomiting in the observation group were significantly lower than the control group＇s. The difference was statistically significant（ P〈0. 05）. Conclusion： Qijiao Shengbai Capsule can improve the bone marrow suppression situation of patients with malignant lymphoma,reduce the incidence of adverse reactionsand ensure the smooth progress of chemotherapy,which is worthy of clinical use.